Hemophilia B, congenital Factor IX deficiency [DS:H00219]
Type
Gene therapy product
Comment
Adeno-associated virus serotype 5 (AAV5) based gene therapy designed to deliver a copy of a gene encoding the Padua variant of human coagulation Factor IX
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
B BLOOD AND BLOOD FORMING ORGANS
B02 ANTIHEMORRHAGICS
B02B VITAMIN K AND OTHER HEMOSTATICS
B02BD Blood coagulation factors
B02BD16 Etranacogene dezaparvovec
D12500 Etranacogene dezaparvovec (USAN/INN) <US>
Drug groups [BR:br08330]
Blood modifier agent
DG02016 Hemostatics
DG02014 Blood coagulation accelerant
DG02013 Blood coagulation factor
D12500 Etranacogene dezaparvovec
Target-based classification of drugs [BR:br08310]
Peptidases and inhibitors
Serine peptidases
Chymotrypsin family
F9
D12500 Etranacogene dezaparvovec (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
Cellular and gene therapy products
D12500
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D12500
Cellular and gene therapy products
D12500
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D12500
